Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Comparing treatments.

Literature DB >> 7773031

Comparing treatments.

D Henry, S Hill.

Abstract

Mesh：

Substances：
Placebos

Year: 1995 PMID： 7773031 PMCID： PMC2549671 DOI： 10.1136/bmj.310.6990.1279

Source DB: PubMed Journal: BMJ ISSN： 0959-8138

× No keyword cloud information.

5 in total

Review 1. Economic evaluation of pharmaceuticals: a European perspective.

Authors: M Drummond; F Rutten; A Brenna; C G Pinto; B Horisberger; B Jönsson; C Le Pen; J Rovira; M G von der Schulenburg; H Sintonen
Journal: Pharmacoeconomics Date: 1993-09 Impact factor: 4.981

2. Support for trials of promising medications through the Pharmaceutical Benefits Scheme. A proposal for a new authority category.

Authors: P P Glasziou
Journal: Med J Aust Date: 1995-01-02 Impact factor: 7.738

3. Promoting cost effective prescribing.

Authors: N Freemantle; D Henry; A Maynard; G Torrance
Journal: BMJ Date: 1995-04-15

4. Generalizing from clinical trials.

Authors: C E Davis
Journal: Control Clin Trials Date: 1994-02

5. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group.

Authors: H J Fuchs; D S Borowitz; D H Christiansen; E M Morris; M L Nash; B W Ramsey; B J Rosenstein; A L Smith; M E Wohl
Journal: N Engl J Med Date: 1994-09-08 Impact factor: 91.245

5 in total

10 in total

1. Pharmacy benefit management: enhancing the applicability of pharmacoeconomics for optimal decision making.

Authors: C Daniel Mullins; Junling Wang
Journal: Pharmacoeconomics Date: 2002 Impact factor: 4.981

2. Availability of comparative trials for the assessment of new medicines in the European Union at the moment of market authorization.

Authors: Johan C F van Luijn; Frank W J Gribnau; Hubert G M Leufkens
Journal: Br J Clin Pharmacol Date: 2006-12-07 Impact factor: 4.335

Comparing treatments.

Review 1. Economic evaluation of pharmaceuticals: a European perspective.

2. Support for trials of promising medications through the Pharmaceutical Benefits Scheme. A proposal for a new authority category.

3. Promoting cost effective prescribing.

4. Generalizing from clinical trials.

5. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group.

1. Pharmacy benefit management: enhancing the applicability of pharmacoeconomics for optimal decision making.

2. Availability of comparative trials for the assessment of new medicines in the European Union at the moment of market authorization.

3. Are research ethics committees behaving unethically? Some suggestions for improving performance and accountability.

4. Confusion over use of placebos in clinical trials.

5. The rights of patients in research.

6. Trials to assess equivalence: the importance of rigorous methods.

7. Superior efficacy of new medicines?

Review 8. WITHDRAWN: Mefloquine for preventing malaria in non-immune adult travellers.

9. Current trends in the cardiovascular clinical trial arena (I).

10. Equivalence and noninferiority trials - are they viable alternatives for registration of new drugs? (III).